Date:7/25/2012

amo for its internal and external research program-related costs. Shire is responsible for clinical development and commercialization of products arising from the alliance.  Shire has paid Sangamo $13.0 million in upfront license fees. In addition, for each gene target, Sangamo is eligible to receive milestone payments upon the achievement of specified research, regulatory clinical development, commercialization and sales milestones as well as royalties on sales of products developed as part of the agreement.

Presentation of Data Showcasing Broad Applications of ZFP Therapeutics. Data from clinical, preclinical and research-stage programs focused on the development of ZFP Therapeutics for HIV/AIDS, monogenic diseases such as hemophilia, hemoglobinopathies and Huntington's disease as well as adoptive T-cell therapies for oncology were described in presentations given by Sangamo scientists and collaborators at the 15th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT).  

Publication in Nature Medicine Demonstrating Use of ZFP Technology to Engineer Safer and More Effective Cancer Treatments. The study advances the development of novel, cell-based therapies for the treatment of a broad range of cancers.

Election of Saira Ramasastry to Sangamo's Board of Directors. At the Annual Meeting of Stockholders held on June 21, 2012, Saira Ramasastry was elected to serve on Sangamo's Board of Directors.  Ms. Ramasastry is the Managing Partner of Life Sciences Advisory, LLC, a company that she founded to provide strategic advice and business development solutions for life science companies. From August 1999 to March 2009, she was an investment banker with Merrill Lynch & Company, Inc. where she helped establish the biotechnology practice and was responsible for origination of mergers and acquisitions, and strategic and capital markets transactions. Prior to her election, Ms. Ramasastry has periodically
'/>"/>

SOURCE Sangamo BioSciences, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2012 Financial Results
2. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
3. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
4. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
5. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
6. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
7. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
8. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
9. Neurocrine Biosciences Reports First Quarter 2012 Results
10. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results